Search Page

1

Cite

Share

OleD Loki as a Catalyst for Hydroxamate Glycosylation.

Hughes RR, Shaaban KA, Ponomareva LV, Horn J, Zhang C, Zhan CG, Voss SR, Leggas M, Thorson JS. Hughes RR, et al. Among authors: leggas m. Chembiochem. 2020 Apr 1;21(7):952-957. doi: 10.1002/cbic.201900601. Epub 2019 Nov 26. Chembiochem. 2020. PMID: 31621997 Free PMC article.

Cite

Share

2

Cite

Share

Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.

Tang F, Ng CM, Bada HS, Leggas M. Tang F, et al. Among authors: leggas m. Clin Transl Sci. 2021 Jul;14(4):1231-1249. doi: 10.1111/cts.12994. Epub 2021 May 1. Clin Transl Sci. 2021. PMID: 33650314 Free PMC article. Review.

Cite

Share

3

Cite

Share

Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent.

Hedrick SL, Luo D, Kaska S, Niloy KK, Jackson K, Sarma R, Horn J, Baynard C, Leggas M, Butelman ER, Kreek MJ, Prisinzano TE. Hedrick SL, et al. Among authors: leggas m. J Biomed Sci. 2021 Sep 9;28(1):62. doi: 10.1186/s12929-021-00758-y. J Biomed Sci. 2021. PMID: 34503531 Free PMC article.

Cite

Share

4

Cite

Share

Predicting Student Success Using In-Program Monitoring.

Ferrante AB, Lambert J, Leggas M, Black EP. Ferrante AB, et al. Among authors: leggas m. Am J Pharm Educ. 2017 Aug;81(6):111. doi: 10.5688/ajpe816111. Am J Pharm Educ. 2017. PMID: 28970612 Free PMC article.

Cite

Share

5

Cite

Share

Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.

Rivas JR, Liu Y, Alhakeem SS, Eckenrode JM, Marti F, Collard JP, Zhang Y, Shaaban KA, Muthusamy N, Hildebrandt GC, Fleischman RA, Chen L, Thorson JS, Leggas M, Bondada S. Rivas JR, et al. Among authors: leggas m. Leukemia. 2021 Nov;35(11):3188-3200. doi: 10.1038/s41375-021-01217-1. Epub 2021 Mar 17. Leukemia. 2021. PMID: 33731852 Free PMC article.

Cite

Share

6

Cite

Share

Stable RNA nanoparticles as potential new generation drugs for cancer therapy.

Shu Y, Pi F, Sharma A, Rajabi M, Haque F, Shu D, Leggas M, Evers BM, Guo P. Shu Y, et al. Among authors: leggas m. Adv Drug Deliv Rev. 2014 Feb;66:74-89. doi: 10.1016/j.addr.2013.11.006. Epub 2013 Nov 22. Adv Drug Deliv Rev. 2014. PMID: 24270010 Free PMC article. Review.

Cite

Share

7

Cite

Share

Mithramycin 2'-Oximes with Improved Selectivity, Pharmacokinetics, and Ewing Sarcoma Antitumor Efficacy.

Liu Y, Eckenrode JM, Zhang Y, Zhang J, Hayden RC, Kyomuhangi A, Ponomareva LV, Cui Z, Rohr J, Tsodikov OV, Van Lanen SG, Shaaban KA, Leggas M, Thorson JS. Liu Y, et al. Among authors: leggas m. J Med Chem. 2020 Nov 25;63(22):14067-14086. doi: 10.1021/acs.jmedchem.0c01526. Epub 2020 Nov 16. J Med Chem. 2020. PMID: 33191745 Free PMC article.

Cite

Share

8

Cite

Share

Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects.

Ye Q, Zhang Y, Cao Y, Wang X, Guo Y, Chen J, Horn J, Ponomareva LV, Chaiswing L, Shaaban KA, Wei Q, Anderson BD, St Clair DK, Zhu H, Leggas M, Thorson JS, She QB. Ye Q, et al. Among authors: leggas m. Cell Chem Biol. 2019 Mar 21;26(3):366-377.e12. doi: 10.1016/j.chembiol.2018.11.013. Epub 2019 Jan 17. Cell Chem Biol. 2019. PMID: 30661989 Free PMC article.

Cite

Share

9

Cite

Share

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.

Adams VR, Leggas M. Adams VR, et al. Among authors: leggas m. Clin Ther. 2007 Jul;29(7):1338-53. doi: 10.1016/j.clinthera.2007.07.022. Clin Ther. 2007. PMID: 17825686 Review.

Cite

Share

10

Cite

Share

Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations.

Liu X, Adane E, Tang F, Leggas M. Liu X, et al. Among authors: leggas m. Biopharm Drug Dispos. 2019 Sep;40(8):265-275. doi: 10.1002/bdd.2199. Epub 2019 Jul 28. Biopharm Drug Dispos. 2019. PMID: 31292985

Cite

Share